Co-Diagnostics posted a GAAP net loss of $6.3 million, or $1.46 per share, in Q2 2026.
Operating loss narrowed to $6.2 million as operating expenses fell to $6.3 million on lower G&A and R&D spending.
Revenue edged up to $166,131, supported by higher product revenue; cash and cash equivalents ended at $3.6 million.
Non-GAAP adjusted EBITDA loss improved to $5.8 million from a $7.2 million loss a year earlier.
The company submitted an FDA 510(k) plus a concurrent CLIA waiver application for its Flu A/B & RSV test; it also expanded Vector Smart installations to 21 states.
CODX•
